You are viewing the site in preview mode

Skip to main content


    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • Published:

Development of a quadruple qRT-PCR assay for simultaneous identification of highly and low pathogenic H7N9 avian influenza viruses and characterization against oseltamivir resistance



During the fifth wave of human H7N9 infections, a novel highly pathogenic (HP) H7N9 variant emerged with an insertion of multiple basic amino acids in the HA cleavage site. Moreover, a neuraminidase inhibitor (NAI) resistance (R292K in NA) mutation was found in H7N9 isolates from humans, poultry and the environment. In this study, we set out to develop and validate a multiplex quantitative reverse transcript polymerase chain reaction (qRT-PCR) to simultaneously detect the presence of H7N9 and further identify the HP and NAI-resistance mutations.


A quadruple qRT-PCR to simultaneously detect the presence of H7N9 and further identify the HP and NAI-resistance mutations was designed based on the analyses of the HA and NA genes of H7N9. This assay was further tested for specificity and sensitivity, and validated using clinical samples.


The assay was highly specific and able to detect low pathogenic (LP)- or HP-H7N9 with/without the NAI-resistance mutation. The detection limit of the assay was determined to be 50 genome-equivalent copies and 2.8 × 10− 3 50% tissue culture infectious doses (TCID50) of live H7N9 per reaction. Clinical validation was confirmed by commercial kits and Sanger sequencing with ten clinical samples.


We developed and validated a rapid, single-reaction, one-step, quadruple real-time qRT-PCR to simultaneously detect the presence of H7N9 and further identify the HP- and NAI-resistance strains with excellent performance in specificity and sensitivity. This assay could be used to monitor the evolution of H7N9 viruses in the laboratory, field and the clinic for early-warning and the prevention of H7N9 infections.


Since human H7N9 infection was first identified in 2013 [1], mainland China has experienced five waves of human infections [2, 3]. H7N9 virus infection caused acute respiratory distress syndrome and resulted in high morbidity and mortality [1, 4]. As of March 27, 2018, a total of 1567 cases of laboratory-confirmed H7N9 virus infections were identified with a case fatality rate of ~ 39% (615 deaths) [5]. During the first four waves, the H7N9 viruses circulating in China were classified as low pathogenic (LP) avian influenza virus (AIV) carrying amino acid residues PKGR/G at the HA cleavage site, causing asymptomatic infection in poultry [4, 6]. However, a highly pathogenic (HP) H7N9 AIV variant emerged during the fifth wave in 2017, and has since been identified in 28 human infections [7,8,9,10]. These HP-H7N9 isolates contained polybasic amino acids with a PKGKRTAR/G, PKGKRIAR/G, PKRKRAAR/G or PKRKRTAR/G in the cleavage site of HA proteins [2], which are associated with enhanced virulence in chickens [2, 11].

Antivirals play an important role in the management of influenza virus infections [12]. Neuraminidase inhibitors (NAIs) have been used as front-line therapeutic options since the novel H7N9 viruses contain the S31N mutation in the M2 protein, which confers resistance to the M2 ion channel blockers such as amantadine [1, 13]. However, studies have shown that the NA R292K (N2 numbering) mutation in H3N2 and H7N9 viruses [13,14,15,16], H274Y (N2 numbering) mutation in the seasonal H1N1, H1N1pdm09 and H5N1 viruses [17,18,19,20,21], emerged during the treatments or through spontaneous changes [14, 22, 23], resulted in a high level of resistance to oseltamivir and other NAIs. Furthermore, H7N9 viruses with the NA R292K mutation were frequently reported in the infected patients, and were usually accompanied by prolonged virus shedding and adverse clinical outcomes [7, 16, 24]. The continuous emergence of NAI-resistant viruses increases the potential threat of the H7N9 viruses to public [25].

Sensitive molecular techniques are needed for the rapid detection of HP-H7N9 variants and NAI-resistance to monitor its circulation, transmission and guide antiviral treatments in clinic. Currently, two qRT-PCR assays have been reported to identify HP-H7 or NAI-resistance mutation of H7N9 virus [26, 27]. However, the application may be restricted by the limit of detection and the circumscribed detection targets. To this end, we developed and validated a multiplex qRT-PCR to simultaneously detect H7N9 and further identify the HP and NAI-resistance strains, and the results are presented herein.


Viruses and RNA extraction

The strains of influenza A and B were previously isolated, and preserved by our group. Viral stocks were prepared in embryonated chicken eggs (Xinxing Dahuanong Biotechnology, Guangzhou, China) with the approval of Animal Ethics Committees from Shenzhen Third People’s Hospital. Viral RNA was extracted from stocks using the QIAamp RNA Viral Kit (Qiagen, Heiden, Germany) according to the manufacturer’s instruction. Viral RNA was eluted in 50 μL of RNA-free buffer and stored at − 80 °C for subsequent use.

Viral stock titration by TCID50

MDCK cells (ATCC, Manassas, USA) in 96-well plates were grown to 90% confluence and infected with 10-fold serial dilutions of the H7N9 chicken embryo allantoic fluid for 1 h at 37 °C. Then the cells were overlaid with fresh DMEM plus TPCK-treated trypsin (2 μg/ml). At 3 days post infection (dpi), plates were assessed for the lowest dilution in which 50% of the wells exhibited cytopathology and HA titer. The 50% tissue culture infectious dose (TCID50) values were calculated according to the Reed-Muench method [28].

Primer and probe design

All the HA and NA sequences of H7N9 used in the present study were downloaded from the NCBI (National Center for Biotechnology Information) and GISAID (Global Initiative on Sharing All Influenza Data), and aligned using the MEGA 7.0 software. Regions covering the insertion mutation in HA cleavage site and the NAI-resistance mutation (R292K) in NA were chosen as the targets for the primer design. The primers and probes were designed using the Primer Premier 5 software. The probes were labeled with four different fluorescent reporter dyes including FAM, VIC, CY5, and ROX at the 5′-end. The FAM and VIC were labeled with the fluorescent quencher dye NFQ-MGB at the 3′-end, while CY5 and ROX were labeled with BHQ. The sequences and genome positions of the primer and probe set are shown in Table 1.

Table 1 Primers and probes used in the multiplex qRT-PCR assay

Generation of DNA standards

A section of the HP-H7 and N9-K292 genes were amplified with the primers H7-F/H7-R and N9-F/N9-R, respectively. The PCR products were purified using the Gene JET PCR Purification Kit (Thermo, MA, USA) and ligated to the pGEM-T vector (Promega, Madison, USA). Plasmids were quantified using the Nanodrop 2000 Spectrophotometer (Thermo, MA, USA). The copy number (molecules/mL) was calculated using the following equation: [C × A / 660 × L], in which C represents the concentration of plasmid (g/mL) assessed by the optical density measurement; A is the Avogadro number (6.023 × 1023); L is the length of the plasmid (number of nucleotides); and 660 is an approximation of the molecular weight of a nucleotide (g/mol).

Quantitative reverse transcription polymerase chain reaction

The samples (both clinical and cultured) were tested by a one-step multiplex qRT-PCR in an ABI QuantStudio Dx Real-Time cycler (Applied Biosystems, Foster City, USA). The One Step PrimeScript™ RT-PCR Kit (Takara, Dalian, China) was used as follows: 0.8 μL enzyme mixture (including reverse transcriptase [RT] and Taq polymerase), 10 μL 2 × One Step RT-PCR buffer III, 0.4 μL of each primer and probe for NA gene, 0.6 μL of each primer for HA gene, 0.6 μL of the universal probe for HA gene (H7-P-W), 0.8 μL of the specific probe for HP-H7 gene (H7-P-M), 0.8 μL RNase free water, and 5 μL RNA (total 20 μL/reaction mixture). The concentration of all the primers and probes was 20 μM. The qRT-PCR assay conditions were as follows: reverse transcription for 5 min at 42 °C; 10 s at 95 °C for reverse transcriptase inactivation and DNA polymerase activation followed by 40 cycles of 5 s at 95 °C and 30 s at 60 °C (annealing-extension step). The data were analyzed using the QuantStudio™ Real-Time PCR Software (Applied Biosystems, Foster City, USA). Commercial qRT-PCR kits for the detection of HP-H7N9 viruses were also used (Mabsky Biotech Co., Ltd., Shenzhen, China; Zhengzhou Zhongdao Biotechnology Co., Ltd., Henan, China) following the manufacturers’ instructions. All samples were analyzed in triplicate with three independent runs.

Clinical samples

Sputum samples were obtained from ten confirmed cases of H7N9 infection in Shenzhen Third People’s Hospital and Yunnan Center for Disease Control and Prevention. Viral RNA was extracted using the QIAamp RNA Viral Kit (Qiagen, Heiden, Germany) according to the manufacturer’s instruction.


Design of the primer-probe set

First, we downloaded and compared the HA genes of the HP- and LP-H7N9 virus. The HA genes of the HP-H7N9 virus possessed either a KRTA, KRIA, or KRAA insertion with a nucleic acid 12 bp in size, 5′-AAA CGG A(G)C(T)T GCG-3′. Thus, we designed the forward (H7-F), reverse (H7-R) primers covering this region, and a probe (H7-P-M) which can specifically recognize the specific insertion. Additionally, a universal probe (H7-P-W) targeting both the HP- and LP-H7N9 within the same region was designed to identify the presence of H7. We then downloaded and compared the NA genes of the H7N9 viruses, selected the forward (N9-F), reverse (N9-R) primers covering the R292K mutation region, and designed a probe (N9-P-M) which can specifically recognize the R292K mutation. Meanwhile, a universal probe (N9-P-W) within the same region was designed to detect the presence of N9 genes. The four probes were labeled with four types of different fluorescence. The oligonucleotide sequences, genome positions, labeled fluorescence of the primers and probes for the multiplex assay are listed in Table 1.

Specificity of the multiplex qRT-PCR assay

The primer-probe set was optimized as a single-well method for H7N9 detection by one-step multiplex qRT-PCR method as described in the Methods section, and the optimized concentrations of the primers and probes are shown in Table 1. To test the specificity of our multiplex qRT-PCR assay, four different H7N9 viruses (LP-H7N9 without NAI-resistance mutation, LP-H7N9 with NAI-resistance mutation, HP-H7N9 without NAI-resistance mutation and HP-H7N9 with NAI-resistance mutation) were used (the identities of viruses used are listed in Table 2). The universal probes of H7 and N9 successfully detected all four phenotypes of H7N9 virus (Fig. 1). Meanwhile, specific probes targeting HP-H7 or N9-K292 specifically recognized the corresponding phenotypes of H7N9 viruses without any nonspecific amplification. In addition, there were also no nonspecific amplification when tested against other influenza viruses (including H1N1, H3N2, H5N6, H6N6 and H9N2 subtype of influenza A and influenza B) (Table 2).

Table 2 The influenza virus strains used in the present study
Fig. 1

Validation and optimization of the multiplex qRT-PCR assay using different H7N9 viruses. (a) Representative amplification plot for viral RNAs from LP-H7N9 without NAI-resistance mutation, (b) LP-H7N9 with NAI-resistance mutation, (c) HP-H7N9 without NAI-resistance mutation and (d) HP-H7N9 with NA inhibitor-resistance mutation. H7-W: detection target for universal H7; H7-M: detection target for highly pathogenic H7; N9-W: detection target for universal N9; N9-M: detection target for R292K mutation of N9

Sensitivity of the multiplex qRT-PCR assay

The detection limit of the multiplex qRT-PCR assay was evaluated by quantitative standards from a pGEM-T vector expressing the target sequence of the HP-H7 and N9-K292 genes, or viral RNAs prepared from serial ten-fold dilutions of the four different phenotypes of H7N9 viral stocks. The multiplex qRT-PCR method using DNA standards as template showed that Ct values were similar among the four targets, and the linear range was between 1 × 106 to 1 × 101 molecules, respectively. Moreover, the regression coefficients (R2) values were above 0.99, indicating that the assay was both accurate and precise over this range (Fig. 2). The limit of detection was determined to be 50 genome-equivalent copies per reaction, based on specific amplification curves (Fig. 2a) and the standard curve (Fig. 2b).

Fig. 2

Sensitivity of the multiplex qRT-PCR assay using DNA standards. (a) Representative amplification plot of the different concentrations of plasmids expressing the targeted H7 or N9 genes (10-fold dilutions). (b) Standard curve for ten-fold serial dilutions of the DNA standards. The log numbers of plasmids (Copies/μL) are expressed linearly on the x-axis, whereas Ct values obtained from qRT-PCR are expressed linearly on the y-axis. H7-W, H7-M, N9-W and N9-M are defined the same with Fig. 1

Meanwhile, RNA samples were extracted from ten-fold serial dilutions of four phenotypes of stock H7N9 viruses ranging from 2 × 106 to 2 × 10− 2 TCID50/mL, and were used to test the detection limit (Figs. 3 and 4). Results showed that the detection limit of the multiplex qRT-PCR assay was similar among the four H7N9 viruses (2.8 × 10− 2 TCID50) per reaction, except for LP-H7N9 without NAI-resistance, which was 2.8 × 10− 3 TCID50 per reaction. The titers correlated well with the obtained Ct values (R2 > 0.99) (Figs. 3 and 4).

Fig. 3

Sensitivity of the multiplex qRT-PCR assay using viral RNAs from LP-H7N9 viruses. (a) Representative amplification plot and standard curves for ten-fold serial dilutions of LP-H7N9 without NAI-resistance mutation strain. (b) Representative amplification plot and standard curves for ten-fold serial dilutions of LP-H7N9 with NAI-resistance mutation strain. The log numbers of live H7N9 viruses (TCID50/mL) are expressed linearly on the x-axis, whereas Ct values are expressed linearly on the y-axis. H7-W, H7-M, N9-W and N9-M are defined the same with Fig. 1

Fig. 4

Sensitivity of the multiplex qRT-PCR assay using viral RNAs from HP-H7N9 viruses. (a) Representative amplification plot and standard curves for ten-fold serial dilutions of HP-H7N9 without NAI-resistance mutation strain. (b) Representative amplification plot and standard curves for ten-fold serial dilutions of HP-H7N9 with NAI-resistance mutation strain. The log numbers of live H7N9 viruses (TCID50/mL) are expressed linearly on the x-axis, whereas Ct values are expressed linearly on the y-axis. H7-W, H7-M, N9-W and N9-M are defined the same with Fig. 1

Validation of the multiplex qRT-PCR assay in clinical samples

To validate the assay with clinical samples, we tested 10 sputum specimens obtained from 10 patients confirmed to be infected with influenza A (H7N9) virus during the fifth wave (Table 3). As expected, all samples tested positive for H7N9 viruses with similar Ct values compared to two commercial kits (Table 3). Furthermore, samples from patients SZ05, SZ07 and SZ08 were determined to be HP-H7N9; and samples from patients SZ04, SZ07 and SZ08 were determined to have NAI-resistance mutations. These results were confirmed by Sanger sequencing.

Table 3 Detection of H7N9 virus in the clinical samples


Previous studies have revealed that the HP-H7N9 virus has caused several outbreaks in poultry farms, in which over 110,000 poultry were found dead in at least 10 provinces [29]. Meanwhile, human infections in rural areas were mostly associated with exposure to sick and dead poultry [8], and the HP-H7N9 variants were also found in the live poultry markets (LPMs) and environment of the human patients [2, 30, 31]. In terms of this situation, the rapid and accurate detection method of HP-H7N9 strains is in urgent need. Recently, one group has developed a duplex qRT-PCR assay to detect both LP-H7 and HP-H7 genes [26]. However, another two novel insertion mutations with “KRIA” or “KRAA” motif in the cleavage site has been found for the HP-H7N9 [2, 8, 11, 30], their probe targeting HP-H7 could not cover all the mutations of HP-H7N9 strains. Furthermore, besides H7, our assay also included the detection target of N9 gene, which could further confirm the presence of H7N9 virus. Except for the broader coverage of probes for HP-H7 and the additional detection target of N9, our assay also possessed an excellent sensitivity. Together, our assay may represent an upgrade of the detection method for HP-H7N9 viruses.

The emergence of an NAI-resistance mutation is temporally associated with a rebound of virus load, treatment failure and a poor clinical outcome [16]. Therefore, identification of the NAI-mutation in time may increase the cure rate for H7N9 infections. Resistance to NAIs in particular has important implications, as this class of agent is most widely used for treatment and outbreak control. Accordingly, appropriate laboratory methods for the continuous efforts of laboratory surveillance are of great importance [12]. Currently, the gold standard methods for antiviral resistance screening include phenotypic and genotypic methods using NA-Star® assay and Sanger sequencing, respectively [32, 33]. While both of these methodologies are labor intensive, time-consuming and expensive, suggesting the need for a rapid, high-throughput approach to influenza drug resistance testing. Although an SNP real-time RT-PCR for detection of NAI-resistance mutation has been developed [27], the application may be restricted in its delayed detection after the identification of H7N9 and the limit of detection. As described in our assay, we can directly determine the presence of LP- or HP-H7N9 viruses and simultaneously identify the NAI resistance with higher detection limit, which significantly improve the efficiency and performance of detection.


In conclusion, we developed and validated a rapid, single-reaction, one-step, quadruple real-time qRT-PCR to simultaneously detect the presence of H7N9 and further identify the HP- and NAI-resistance strains with excellent performance in specificity and sensitivity. As the ongoing circulation of H7N9 viruses among poultry, enhanced surveillance is critical to guide prevention and control efforts. This assay will be of great use in monitoring the circulation of HP-H7N9 and NAI-resistant virus strains during AIV surveillance and the treatment of patients with NAIs to prevent persistent viral replication and severe inflammatory reactions.



Avian influenza virus


Highly pathogenic


Low pathogenic


Neuraminidase inhibitor


Quantitative reverse transcript polymerase chain reaction


Single nucleotide polymorphism

TCID50 :

50% tissue culture infectious dose


  1. 1.

    Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, et al. Human infection with a novel avian-origin influenza a (H7N9) virus. N Engl J Med. 2013;368(20):1888–97.

  2. 2.

    Quan CS, Shi WF, Yang Y, Yang YC, Liu XQ, Xu W, Li H, Li J, Wang QL, Tong Z, et al. New threats of H7N9 influenza virus: the spread and evolution of highly and low pathogenic variants with high genomic diversity in Wave Five. J Virol. 2018;92(11). pii: e00301–18.

  3. 3.

    Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, Wang L, Huo X, Xu K, Chen E, et al. Epidemiology of avian influenza a H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis. 2017;17(8):822–32.

  4. 4.

    Su S, Gu M, Liu D, Cui J, Gao GF, Zhou J, Liu X. Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China. Trends Microbiol. 2017;25(9):713–28.

  5. 5.

    WHO. Monthly risk assessment summary. 2017. Accessed 4 Nov 2017.

  6. 6.

    Liu J, Xiao H, Wu Y, Liu D, Qi X, Shi Y, Gao GF. H7N9: a low pathogenic avian influenza a virus infecting humans. Curr Opin Virol. 2014;5:91–7.

  7. 7.

    Yang JR, Liu MT. Human infection caused by an avian influenza a (H7N9) virus with a polybasic cleavage site in Taiwan, 2017. J Formos Med Assoc. 2017;116(3):210–2.

  8. 8.

    Zhang F, Bi Y, Wang J, Wong G, Shi W, Hu F, Yang Y, Yang L, Deng X, Jiang S, et al. Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China. J Inf Secur. 2017;75(1):71–5.

  9. 9.

    Zhou L, Tan Y, Kang M, Liu F, Ren R, Wang Y, Chen T, Yang Y, Li C, Wu J, et al. Preliminary epidemiology of human infections with highly pathogenic avian influenza a(H7N9) virus, China, 2017. Emerg Infect Dis. 2017;23(8):1355–9.

  10. 10.

    Kile JC, Ren R, Liu L, Greene CM, Roguski K, Iuliano AD, Jang Y, Jones J, Thor S, Song Y, et al. Update: increase in human infections with novel asian lineage avian influenza a(H7N9) viruses during the fifth epidemic - China, October 1, 2016-august 7, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(35):928–32.

  11. 11.

    Qi W, Jia W, Liu D, Li J, Bi Y, Xie S, Li B, Hu T, Du Y, Xing L et al. Emergence and adaptation of a novel highly pathogenic H7N9 influenza virus in birds and humans from a 2013 human-infecting low-pathogenic ancestor. J Virol. 2018;92(2). pii: e00921–17.

  12. 12.

    Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929–44.

  13. 13.

    Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, Fry AM, Gubareva LV. Neuraminidase mutations conferring resistance to oseltamivir in influenza a(H7N9) viruses. J Virol. 2015;89(10):5419–26.

  14. 14.

    Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antivir Res. 2017;146:12–20.

  15. 15.

    Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J, et al. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res. 2013;23(12):1347–55.

  16. 16.

    Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, et al. Association between adverse clinical outcome in human disease caused by novel influenza a H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381(9885):2273–9.

  17. 17.

    Nguyen HT, Nguyen T, Mishin VP, Sleeman K, Balish A, Jones J, Creanga A, Marjuki H, Uyeki TM, Nguyen DH, et al. Antiviral susceptibility of highly pathogenic avian influenza a(H5N1) viruses isolated from poultry, Vietnam, 2009-2011. Emerg Infect Dis. 2013;19(12):1963–71.

  18. 18.

    Govorkova EA, Baranovich T, Seiler P, Armstrong J, Burnham A, Guan Y, Peiris M, Webby RJ, Webster RG. Antiviral resistance among highly pathogenic influenza a (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antivir Res. 2013;98(2):297–304.

  19. 19.

    Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, Maeda T, Tanaka O, Doniwa K, Iwakuni O, et al. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation. J Infect Chemother. 2012;18(2):180–6.

  20. 20.

    Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011;7(10):e1002249.

  21. 21.

    Kawai N, Ikematsu H, Iwaki N, Kondou K, Hirotsu N, Kawashima T, Maeda T, Tanaka O, Doniwa K, Kashiwagi S. Clinical effectiveness of oseltamivir for influenza a(H1N1) virus with H274Y neuraminidase mutation. J Inf Secur. 2009;59(3):207–12.

  22. 22.

    Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, Barr IG, McKimm-Breschkin JL. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother. 2006;50(5):1872–4.

  23. 23.

    Meijer A, Jonges M, van Beek P, Swaan CM, Osterhaus AD, Daniels RS, Hurt AC, Koopmans MP. Oseltamivir-resistant influenza a(H1N1)pdm09 virus in Dutch travellers returning from Spain, august 2012. Euro Surveill. 2012;17(36):20266.

  24. 24.

    Ke C, Mok CKP, Zhu W, Zhou H, He J, Guan W, Wu J, Song W, Wang D, Liu J, et al. Human infection with highly pathogenic avian influenza a(H7N9) virus. China Emerg Infect Dis. 2017;23(8):1332–40.

  25. 25.

    Danqi B, Li Z, Liu Q, Richt JA. H7N9 avian influenza a virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs. Expert Rev Anti-Infect Ther. 2017;15(8):723–7.

  26. 26.

    Jia W, Cao C, Lin Y, Zhong L, Xie S, Wang X, Yin S, Xu Z, Dai Y, Li Z, et al. Detection of a novel highly pathogenic H7 influenza virus by duplex real-time reverse transcription polymerase chain reaction. J Virol Methods. 2017;246:100–3.

  27. 27.

    Wang W, Song Z, Guan W, Liu Y, Zhang X, Xu L, Li J, Yuan Z, Hu Y. PCR for detection of oseltamivir resistance mutation in influenza a(H7N9) virus. Emerg Infect Dis. 2014;20(5):847–9.

  28. 28.

    Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493–7.

  29. 29.

    OIE. Update on avian influenza in animals (types H5 and H7). 2017. Accessed 4 Nov 2017.

  30. 30.

    Yang L, Zhu W, Li X, Chen M, Wu J, Yu P, Qi S, Huang Y, Shi W, Dong J et al. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in mainland China. J Virol. 2017;91(23). pii: e01277–17.

  31. 31.

    Shi J, Deng G, Kong H, Gu C, Ma S, Yin X, Zeng X, Cui P, Chen Y, Yang H, et al. H7N9 virulent mutants detected in chickens in China pose an increased threat to humans. Cell Res. 2017;27(12):1409–21.

  32. 32.

    Meijer A, Lackenby A, Hay A, Zambon M. Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro Surveill. 2007;12(4):E3–4.

  33. 33.

    Wong S, Pabbaraju K, Wong A, Fonseca K, Drews SJ. Development of a real-time RT-PCR assay for detection of resistance to oseltamivir in influenza a pandemic (H1N1) 2009 virus using single nucleotide polymorphism probes. J Virol Methods. 2011;173(2):259–65.

Download references


We thank the staff of our hospital for their assistance in sample collection and laboratory work.


This work was supported by grants from the National Key Research and Development Project of China (2016YFE0205800), National Science and Technology Major Project (2016ZX10004222), Emergency Technology Research Issue on Prevention and Control for Human Infection with A(H7N9) Avian Influenza Virus (10600100000015001206), Sanming Project of Medicine in Shenzhen (ZDSYS201504301534057), Shenzhen Science and Technology Research and Development Project (JCYJ20160427153238750 and JCYJ20160427151920801), intramural special grant for influenza virus research from the Chinese Academy of Sciences (KJZD-EW-L15) and Science and Technology plan project of Shenzhen (201506048 and 20160625). G.F.G. is a leading principal investigator of the NSFC Innovative Research Group (81621091). Y.B. is supported by the Youth Innovation Promotion Association of Chinese Academy of Sciences (2017122). The funding bodies had no roles in the design of the study, or the collection, analysis and interpretation of data, or writing the manuscript.

Availability of data and materials

Full-length genome sequences of the ten H7N9 viruses isolated from the clinical samples in our study have been deposited into GISAID EpiFlu: EPI_ISL_250312–17, EPI_ISL_250424–25, EPI_ISL_259757, and EPI_ISL_266936.

Author information

YB and YY designed the experiments. YY, SL, GW, SM and ZX performed the experiments and results analysis. XZ, WX, HL, HZ, JL and QZ recruited the patients, performed clinical monitoring, and provided clinical expertise. WL, YL and GFG provided technical support. YY, GW and YB wrote the manuscript, and all authors provided critical review and approved the manuscript.

Correspondence to Yuhai Bi.

Ethics declarations

Ethics approval and consent to participate

The study was performed in accordance with guidelines approved by the Ethics Committees from Shenzhen Third People’s Hospital (SZTHEC2016001) and Yunnan Center for Disease Control and Prevention Ethics Committee (YNCDC2017001), and verbal informed consents were obtained from all patients or patients’ family members.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark


  • Highly/low pathogenic avian influenza virus
  • H7N9
  • Quadruple qRT-PCR
  • Molecular diagnostics
  • NAI-resistance
  • Oseltamivir